XOMA to Present at the 42nd Annual Cowen Health Care Conference
01 mars 2022 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA to Present at Aegis Capital Corp Investor Conference
17 févr. 2022 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA Declares Quarterly Preferred Stock Dividends
23 déc. 2021 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA to Present at Upcoming Investor Conferences
21 déc. 2021 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA Announces Evolution of Company Leadership and Succession Planning
16 déc. 2021 07h30 HE
|
XOMA Corporation
Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director Company is launching Chief Executive Officer search; Jim...
XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer
04 nov. 2021 07h40 HE
|
XOMA Corporation
EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3...
XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events
04 nov. 2021 07h30 HE
|
XOMA Corporation
Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the treatment of...
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
22 sept. 2021 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)’s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare...
XOMA Declares Quarterly Preferred Stock Dividends
20 sept. 2021 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference
13 sept. 2021 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global...